Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung County, Taiwan, Republic of China.
J Ocul Pharmacol Ther. 2010 Aug;26(4):341-5. doi: 10.1089/jop.2009.0135.
To evaluate the efficacy of 0.025% atropine solution for prevention of myopic shift and myopia onset in premyopic children.
This study was designed as a retrospective cohort study. Six- to 12-year-old children with spherical equivalent refraction of <+1 diopter (D) (defined as premyopia), with cylindrical refraction of <-1 D, without amblyopia, and who received 0.025% atropine eye drops at bedtime every night or no treatment after follow-up for at least 12 months were enrolled. Fast myopic shift is defined as a myopic shift >-0.5 D per year.
Fifty children were enrolled in the study. Twenty-four children (average age 7.6 years old) were in the 0.025% atropine group, and 26 children (average age: 8.2 years old) were in the control group. The mean spherical refraction myopic shift in the 0.025% atropine group was -0.14 +/- 0.24 D/year, significantly lower than that in the control group, -0.58 +/- 0.34 D/year (P < 0.0001). In multiple linear regression analysis, 0.025% atropine treatment was the only independent variable in preventing myopia shift. There were statistically significant differences between the 0.025% atropine group and the control group in myopia onset and fast myopic shift (21% vs. 54%, P = 0.016; 8% vs. 58%, P = 0.0002, respectively). There was no difference between the 2 groups with regard to the symptom of photophobia (16% vs. 8%, P = 0.409). None of the children in either group complained of near-blurred vision.
Regular topical administration of 0.025% atropine eye drops can prevent myopia onset and myopic shift in premyopic schoolchildren for a 1-year period.
评估 0.025%阿托品溶液预防近视儿童近视进展和近视发生的疗效。
本研究设计为回顾性队列研究。纳入 6 至 12 岁、等效球镜屈光度<+1 屈光度（定义为近视前期）、柱镜屈光度<-1 屈光度、无弱视且随访至少 12 个月后每晚睡前使用 0.025%阿托品滴眼或未接受治疗的儿童。近视快速进展定义为每年近视进展>-0.5 D。
共纳入 50 名儿童。24 名儿童（平均年龄 7.6 岁）入 0.025%阿托品组，26 名儿童（平均年龄：8.2 岁）入对照组。0.025%阿托品组平均球镜近视屈光度进展为-0.14 +/- 0.24 D/年，明显低于对照组的-0.58 +/- 0.34 D/年（P<0.0001）。多元线性回归分析显示，0.025%阿托品治疗是预防近视进展的唯一独立变量。0.025%阿托品组和对照组在近视发生和近视快速进展方面有统计学差异（21%比 54%，P=0.016；8%比 58%，P=0.0002）。两组畏光症状（16%比 8%，P=0.409）无差异。两组均无儿童报告近视力模糊。
定期局部使用 0.025%阿托品滴眼可预防近视前期学龄儿童 1 年内近视发生和近视进展。
